蛋白激酶抑制剂的模型引导精准给药:模型平均与平坦先验方法评估
本研究基于41例肾癌患者(SUP-R试验)的浓度数据,评估舒尼替尼和帕唑帕尼的模型引导精准给药(MIPD),比较不同文献模型及模型平均、平坦先验方法预测稳态谷浓度(Cmin,ss)的表现。结果显示预测质量取决于所用模型,模型平均在不同场景下稳健,应优先于单一模型;总体精度达20%至25%,偏倚小于5%。
要点
- 模型平均法在舒尼替尼和帕唑帕尼的MIPD中表现稳健,应优先于单一模型。
- Cmin,ss预测精度达20%至25%,偏倚小于5%。
- 平坦先验方法对预测改善或恶化影响不大。
核心结论
- 模型平均法用于舒尼替尼和帕唑帕尼的MIPD具有稳健性,可能适用于其他蛋白激酶抑制剂。
研究设计与样本
- 基于SUP-R试验(NCT02555748)中41例肾癌患者给药后2和6小时的浓度数据,采用MAP贝叶斯估计预测当前周期和下一周期的Cmin,ss。
- 测试文献中不同模型,以及R包「mapbayr」中的模型平均和平坦先验功能。
主要发现
- Cmin,ss预测质量取决于所用模型。
- 平坦先验很少改善或恶化预测。
- 模型平均在不同测试场景中表现稳健。
- 总体精度达20%至25%,最小偏倚小于5%。
临床怎么用
- 在临床MIPD中,当多个模型可用时,优先采用模型平均法而非单一模型。
- 该框架已通过「mapbayr」实现为独立shiny应用,可供临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Therapeutic drug monitoring of protein kinase inhibitors (PKIs) usually relies on the measure of a single trough concentration at steady-state (Cmin,ss). When the sampling time differs from the trough, it is theoretically possible to predict Cmin,ss from maximum a posteriori (MAP) Bayesian estimates of PK parameters. However, several questions remain with regards to model-informed precision dosing (MIPD) of PKIs, such as choosing which model to use when several are available in the literature. Alternative techniques, such as flattened priors and model averaging may outperform standard analyses. The aim of this work is to report a comprehensive fit-for-purpose validation of MIPD for sunitinib and pazopanib. METHODS: Concentration data from 41 renal cancer patients included in the SUP-R trial (NCT02555748) measured 2 and 6 hours after an intake were analyzed (MAP-Bayesian estimation of PK parameters) in order to predict Cmin,ss at the current cycle and at the next cycle. Different models from the literature were tested, as well as the model-averaging and flattened priors features available in the R package 'mapbayr'. RESULTS: The quality of Cmin,ss predictions depended on the model used. Flattening priors rarely improved or worsened the predictions. Model averaging was robust across the different scenarios tested and should be preferred to using a single model. Overall, a precision of 20% to 25% was achieved, with a minimal bias (< 5%). CONCLUSION: The benefit of the model-averaging method for the model-informed precision dosing of sunitinib and pazopanib is likely applicable to other protein kinase inhibitors. Thanks to 'mapbayr', this framework was implemented as a standalone shiny application to be used in clinical settings.
引用
- Le Louedec F, Morvan L, Mourey L, et al. Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods. Clin Pharmacokinet. 2026. PMID: 41801644. doi:10.1007/s40262-026-01628-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。